Key result
The choice of glucose-lowering agents in patients with diabetes can substantially affect heart failure-related outcomes, with SGLT-2 inhibitors reducing heart failure hospitalizations while thiazolidinediones increase the risk.
Why the study?
Does the choice of antihyperglycemic drugs affect heart failure-related outcomes in patients with diabetes?
Does the choice of antihyperglycemic drugs affect heart failure-related outcomes in patients with diabetes?
This review highlights the critical importance of selecting appropriate glucose-lowering therapies, such as SGLT-2 inhibitors, to mitigate the high risk of heart failure in patients with diabetes.
May inform agent selection to mitigate HF risk in diabetes; leaves open prospective confirmation before practice change.
To summarize current clinical data investigating the link between diabetes and heart failure pathophysiology, the association of glucose control with heart failure, and the impact of current antihyperglycemic drugs on heart failure. Although heart failure is one of the most prevalent outcomes occurring in real life and cardiovascular outcome trials, insufficient attention was given to this condition in diabetes research over the last decades. With both beneficial and detrimental findings for heart failure hospitalization in the health authority–mandated outcome trials for new antihyperglycemic agents, research on heart failure and its interplay with diabetes mellitus gained momentum. Diabetes mellitus and heart failure are both prevalent and intertwined conditions. While currently available heart failure therapies have a similar degree of effectiveness in patients with and without diabetes, the choice of glucose-lowering agents can substantially affect heart failure-related outcome.
No takes yet. Share an insight, caveat, or question.
Wallner et al. (2018) conducted a review in Diabetes mellitus and heart failure. Antihyperglycemic drugs was evaluated. The choice of glucose-lowering agents in patients with diabetes can substantially affect heart failure-related outcomes, with SGLT-2 inhibitors reducing heart failure hospitalizations while thiazolidinediones increase the risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: